JP2010501188A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501188A5 JP2010501188A5 JP2009525796A JP2009525796A JP2010501188A5 JP 2010501188 A5 JP2010501188 A5 JP 2010501188A5 JP 2009525796 A JP2009525796 A JP 2009525796A JP 2009525796 A JP2009525796 A JP 2009525796A JP 2010501188 A5 JP2010501188 A5 JP 2010501188A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- rna molecule
- interfering rna
- nucleotides
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 46
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 39
- 230000002452 interceptive effect Effects 0.000 claims 39
- 239000002773 nucleotide Substances 0.000 claims 26
- 125000003729 nucleotide group Chemical group 0.000 claims 26
- 108020004999 messenger RNA Proteins 0.000 claims 15
- 102100038367 Gremlin-1 Human genes 0.000 claims 12
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 claims 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 108091027967 Small hairpin RNA Proteins 0.000 claims 5
- 239000004055 small Interfering RNA Substances 0.000 claims 5
- 230000000699 topical effect Effects 0.000 claims 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- 230000009368 gene silencing by RNA Effects 0.000 claims 3
- 108091070501 miRNA Proteins 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 239000002924 silencing RNA Substances 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 108091081021 Sense strand Proteins 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 210000000795 conjunctiva Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83982606P | 2006-08-24 | 2006-08-24 | |
| PCT/US2007/076776 WO2008024983A2 (en) | 2006-08-24 | 2007-08-24 | Rnai-mediated inhibition of gremlin for treatment of iop-related conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010501188A JP2010501188A (ja) | 2010-01-21 |
| JP2010501188A5 true JP2010501188A5 (https=) | 2010-08-12 |
Family
ID=39032079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009525796A Pending JP2010501188A (ja) | 2006-08-24 | 2007-08-24 | IOPに関連した病態の処置のためのグレムリンのRNAi媒介阻害 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20080051361A1 (https=) |
| EP (1) | EP2059597A2 (https=) |
| JP (1) | JP2010501188A (https=) |
| KR (1) | KR20090042297A (https=) |
| CN (2) | CN102743767A (https=) |
| AU (1) | AU2007286545A1 (https=) |
| BR (1) | BRPI0715821A2 (https=) |
| CA (1) | CA2659464A1 (https=) |
| MX (1) | MX2009001896A (https=) |
| WO (1) | WO2008024983A2 (https=) |
| ZA (1) | ZA200900553B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| GB0708662D0 (en) * | 2007-05-04 | 2007-06-13 | Galapagos Nv | shRNA sequences |
| RU2010117178A (ru) * | 2007-10-01 | 2011-11-10 | Алькон Рисерч, Лтд. (Us) | Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний |
| BRPI0802525A2 (pt) | 2008-07-11 | 2010-03-09 | Kiyoshi Hashiba | endoscópio cirúrgico |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| EP2510098B1 (en) * | 2009-12-09 | 2015-02-11 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
| CN106074591B (zh) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | 眼部症候中的rna干扰 |
| KR101722948B1 (ko) | 2012-01-05 | 2017-04-04 | (주)바이오니아 | 리간드가 결합된 이중나선 올리고 rna 구조체 및 그 제조방법 |
| CA2859127C (en) | 2011-12-15 | 2017-04-25 | Bioneer Corporation | Novel oligonucleotide conjugates and use thereof |
| CN104114704A (zh) | 2012-01-05 | 2014-10-22 | 株式会社百奥尼 | 高效率的纳米颗粒型双螺旋寡rna结构体及其制备方法 |
| WO2013109057A1 (ko) | 2012-01-18 | 2013-07-25 | (주)바이오니아 | 자성나노입자-samirna 복합체 및 그 제조방법 |
| JP6339063B2 (ja) | 2012-03-15 | 2018-06-06 | エスエヌユー アールアンドディービー ファウンデーション | グレムリン−1に対する抗体 |
| SG11201501385UA (en) * | 2012-09-05 | 2015-03-30 | Sylentis Sau | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| GB201215857D0 (en) * | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| CN105705638B (zh) | 2013-07-05 | 2019-11-26 | 柏业公司 | 改善的具有高效能的纳米颗粒型寡核苷酸结构及其制备方法 |
| US10011837B2 (en) | 2014-03-04 | 2018-07-03 | Sylentis Sau | SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
| JP2017200928A (ja) * | 2017-05-31 | 2017-11-09 | シレンティス・エセ・ア・ウ | siRNAならびに眼の状態の処置および/または予防のための方法および組成物におけるその使用 |
| CN106978509B (zh) * | 2017-06-07 | 2018-10-26 | 中南大学湘雅二医院 | 青光眼诊断分子标记物lncRNAs ENST00000607393、试剂盒及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101072867B1 (ko) * | 2001-10-31 | 2011-10-17 | 유니버시티 오브 노스 텍사스 헬스 사이언스 센터 | 뼈 형태발생 단백질(bmp), bmp 수용체 및 bmp 결합 단백질 및 녹내장 진단 및 치료에서 그의 용도 |
| US20040138163A1 (en) * | 2002-05-29 | 2004-07-15 | Mcswiggen James | RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| TW200639252A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
-
2007
- 2007-08-24 CN CN2012102535702A patent/CN102743767A/zh active Pending
- 2007-08-24 AU AU2007286545A patent/AU2007286545A1/en not_active Abandoned
- 2007-08-24 CA CA002659464A patent/CA2659464A1/en not_active Abandoned
- 2007-08-24 WO PCT/US2007/076776 patent/WO2008024983A2/en not_active Ceased
- 2007-08-24 ZA ZA200900553A patent/ZA200900553B/xx unknown
- 2007-08-24 CN CNA2007800308171A patent/CN101517081A/zh active Pending
- 2007-08-24 US US11/844,869 patent/US20080051361A1/en not_active Abandoned
- 2007-08-24 MX MX2009001896A patent/MX2009001896A/es active IP Right Grant
- 2007-08-24 EP EP07841339A patent/EP2059597A2/en not_active Withdrawn
- 2007-08-24 JP JP2009525796A patent/JP2010501188A/ja active Pending
- 2007-08-24 KR KR1020097004684A patent/KR20090042297A/ko not_active Ceased
- 2007-08-24 BR BRPI0715821-1A patent/BRPI0715821A2/pt not_active IP Right Cessation
-
2010
- 2010-06-02 US US12/791,926 patent/US20100305193A1/en not_active Abandoned
-
2011
- 2011-10-26 US US13/281,785 patent/US20120077864A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010501188A5 (https=) | ||
| RU2008130857A (ru) | Опосредованное phkи ингибирование hif1a для лечения глазного ангиогенеза | |
| RU2008150324A (ru) | Iphk-опосредованное ингибирование связанных с фактором некроза опухоли альфа состояний | |
| RU2011124528A (ru) | ОПОСРЕДОВАННОЕ PHKI ИНГИБИРОВАНИЕ Rho-КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ НАРУШЕНИЙ | |
| JP2008525460A5 (https=) | ||
| Guzman‐Aranguez et al. | Small‐interfering RNA s (siRNA s) as a promising tool for ocular therapy | |
| RU2007132874A (ru) | Phki-опосредованное ингибирование мишеней повышенного внутриглазного давления | |
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー | |
| JP2009533475A5 (https=) | ||
| JP2009540011A5 (https=) | ||
| JP2012072152A5 (https=) | ||
| US20100305193A1 (en) | Rnai-mediated inhibition of gremlin for treatment of iop-related conditions | |
| JP2010540564A5 (https=) | ||
| JP2006505251A5 (https=) | ||
| JP2022185052A5 (https=) | ||
| RU2010117178A (ru) | Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний | |
| JP2013540770A5 (https=) | ||
| JP2008533050A5 (https=) | ||
| JP2022501044A5 (https=) | ||
| US20150057336A1 (en) | RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA | |
| US20110190376A1 (en) | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA | |
| JP2009533466A5 (https=) | ||
| WO2015030616A4 (en) | Use of nucleic acid molecules in therapy of diseases induced by expansion of trinucleotide cag repeats | |
| CN101124322B (zh) | 用于治疗青光眼的血清淀粉状蛋白A的RNAi抑制 | |
| WO2008092142A2 (en) | Rnai-mediated inhibition of aquaporin 1 for treatment of ocular neovascularization |